Riboxx PHARMA : Switching IMMUNITY ON
MissionRiboxx develops new class of drugs to treat cancer, virus infections or autoimmune diseases.
The drugs developed at Riboxx act by switching the immune system ON. This is achieved by triggering activation of the so called "innate immune system". The innate immune system is the first line of defense of the body. It is also the oldest immune defense strategy, and is found in all classes of animal life. It is a non-specific immune system, (i.e. not specific for one pathogen), being triggered by molecular patterns, such as double-stranded RNA (dsRNA).
Immune cells playing an important role in innate immunity include dendritic cells, macrophages, neutrophils, and Natural Killer cells. These cells are directly implicated in mounting a potent immune response to cancer or virus infections.
The drugs developed at Riboxx belong to the class of Toll-like-Receptor agonists (TLR) and RIG-I-like-Receptor (RLR) agonists. The Active Pharmaceutical Ingredient (API) of these drugs is RNA (Ribonucleic acid).
So far, Riboxx has developed two families of TLR & RLR agonists with indications in the fields of oncology, virus infections and autoimmune disorders.
The development pipeline at Riboxx comprises:
- RIBOXXIM® compounds, for treatment of cancer or virus infections
- RIBOXXON® compounds, for treatment of cancer and autoimmune diseases
RIBOXXIM® and RIBOXXON® include more than 20 proprietary API that possess unique properties as to potency, analytical purity, bioavailability, and safety.
Partnerships represent an essential element of Riboxx business strategy. These technologies are available for pharmaceutical companies for out-licensing in their specific indications.
If you are interested in entering a CDA for more information on our technologies or testing the API under MTA, please contact us at firstname.lastname@example.org.